Stifel Reiterates Buy on Medivation (MDVN) Following Talazoparib Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
August 24, 2015 7:00 AM EDTTalazoparib is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer Clinical Activity Observed in Multiple Oncology Opportunities with Potential for monotherapy or Combination therapy with Standard of Care Oncology Treatments Transaction Price of $410 Million Upfront, Up to $160 Million in Milestones and Mid-Single Digit Royalties
SAN FRANCISCO and SAN RAFAEL, Calif., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Medivation, Inc. (Nasdaq: MDVN) and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that they have entered into an asset purchase agreement under... More
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
August 24, 2015 7:00 AM EDTSAN FRANCISCO, CA and SAN RAFAEL, CA -- (Marketwired) -- 08/24/15 -- Medivation, Inc. (NASDAQ: MDVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that they have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research,... More
